Infants with MLL-rearranged infant acute lymphoblastic leukemia (MLL-r iALL) undergo intense therapy to counter a highly aggressive malignancy with survival rates of only 30–40%. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.